AtaiBeckley Inc.

Subsidiary of Eli Lilly (LLY)

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
5-HT2A receptorSmall molecule
Major Depressive Disorder
Treatment-Resistant Depression
Phase 2
Serotonergic system (MDMA-class entactogen)Small molecule
Social Anxiety Disorder
Phase 2
5-HT2A receptorSmall molecule
Major Depressive Disorder
Treatment-Resistant Depression

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 February 2026Topline resultEMP-01EMP-01 Phase 2a topline in social anxiety disorder (placebo-adjusted LSAS -11.85 at Day 43)
US · AtaiBeckley Inc. · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.7M$28M$169M$33Mreport ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0.9M$17M$43M$30Mreport ↗
2025-Q2$0.7M$11M$62M$28Mreport ↗
2025-Q1$1.6M$11M$58M$26Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.1M$53M$85M$165Mreport ↗

AtaiBeckley reported full-year 2025 revenue of $4.09M, up 1219.4% YoY, with R&D spend of $53.06M, down 4.3% YoY. Cash and equivalents were $85.3M, and the company reported a net loss of $660.05M.

Management expects existing cash to fund operations into 2029, covering planned topline readouts from both Phase 3 pivotal studies. BPL-003 Phase 3 initiation remains on track for Q2 2026 following a successful End of Phase 2 meeting with the FDA, VLS-01 Phase 2 Elumina topline data are anticipated in H2 2026, and the exploratory Phase 2a trial of EMP-01 in social anxiety disorder met its primary safety and tolerability objective with clinically meaningful efficacy improvements. Key events included the November 2025 strategic combination with Beckley Psytech, U.S. redomiciliation, and inclusion in the NASDAQ Biotechnology Index.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.3M$55M$28M$37Mreport ↗
2023-FY——$45M—report ↗